For example, 7 of the 25 (28%) prostate cancers with KLF5 deep deletion in the TCGA database and 4 of the 11 (36%) metastatic prostate cancers in another database also have PTEN deep deletion or truncating mutation [53], as revealed by the cBioPortal analysis [54,55]. This evidence concerns the gene KLF5 and metastatic prostate carcinoma.